L3VLUP
ProSign in

TECH · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TECHGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TECH
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterTECHGILD
Q3 202014 holders, $1.2bn25 holders, $14.2bn
Q4 202010 holders, $1.2bn27 holders, $13.4bn
Q1 202111 holders, $1.5bn24 holders, $14.5bn
Q2 20216 holders, $1.4bn18 holders, $14.9bn
Q3 20218 holders, $1.5bn20 holders, $16.4bn
Q4 20219 holders, $1.9bn20 holders, $16.8bn
Q1 20227 holders, $1.3bn28 holders, $13.2bn
Q2 202213 holders, $1.3bn26 holders, $13.6bn
Q3 202213 holders, $1.0bn24 holders, $13.3bn
Q4 20229 holders, $954m32 holders, $21.1bn
Q1 202315 holders, $896m27 holders, $21.8bn
Q2 202310 holders, $1.2bn24 holders, $20.7bn
Q3 202310 holders, $960m24 holders, $20.0bn
Q4 202310 holders, $1.2bn22 holders, $21.5bn
Q1 20248 holders, $1.2bn30 holders, $20.3bn
Q2 20247 holders, $1.4bn28 holders, $18.5bn
Q3 202410 holders, $2.1bn29 holders, $24.2bn
Q4 20248 holders, $1.7bn28 holders, $25.9bn
Q1 20258 holders, $1.2bn33 holders, $32.0bn
Q2 20258 holders, $860m27 holders, $30.9bn
Q3 202514 holders, $1.4bn23 holders, $29.4bn
Q4 202513 holders, $1.7bn25 holders, $34.3bn
Q1 202610 holders, $1.6bn25 holders, $38.5bn
Q2 202621 holders, $2.6bn26 holders, $34.2bn
TECH

Bio-techne Corp

Holders
21
Reported value
$2.6bn
Buyers
24
Sellers
18

Breadth +6 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
26
Reported value
$34.2bn
Buyers
22
Sellers
16

Breadth +6 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2026

Among the 37 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TECH (11)

Caxton Associates LLP, Durable Capital Partners LP, Glenview Capital Management LLC, Hudson Bay Capital Management LP, Maverick Capital Ltd, Moore Capital Management LP, Ruane Cunniff & Goldfarb LP, Soros Fund Management LLC, Tudor Investment Corp, Verition Fund Management LLC, Winton Group Ltd

Only GILD (16)

Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Holocene Advisors LP, Janus Henderson Group Ltd, Millennium Management LLC, Point72 Asset Management LP, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →